Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C5H6O5 |
| Molecular Weight | 146.0981 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CCC(=O)C(O)=O
InChI
InChIKey=KPGXRSRHYNQIFN-UHFFFAOYSA-N
InChI=1S/C5H6O5/c6-3(5(9)10)1-2-4(7)8/h1-2H2,(H,7,8)(H,9,10)
| Molecular Formula | C5H6O5 |
| Molecular Weight | 146.0981 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/27416627 | https://www.ncbi.nlm.nih.gov/pubmed/18161514http://naturaldatabase.therapeuticresearch.com/nd/PrintVersion.aspx?id=144&AspxAutoDetectCookieSupport=1Curator's Comment: Description was created based on several sources, including
http://www.uofmhealth.org/health-library/hn-4451004 | https://www.ncbi.nlm.nih.gov/pubmed/27326424 | https://www.ncbi.nlm.nih.gov/pubmed/26122777 | https://www.ncbi.nlm.nih.gov/pubmed/26759695 | https://www.ncbi.nlm.nih.gov/pubmed/10453328
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27416627 | https://www.ncbi.nlm.nih.gov/pubmed/18161514http://naturaldatabase.therapeuticresearch.com/nd/PrintVersion.aspx?id=144&AspxAutoDetectCookieSupport=1
Curator's Comment: Description was created based on several sources, including
http://www.uofmhealth.org/health-library/hn-4451004 | https://www.ncbi.nlm.nih.gov/pubmed/27326424 | https://www.ncbi.nlm.nih.gov/pubmed/26122777 | https://www.ncbi.nlm.nih.gov/pubmed/26759695 | https://www.ncbi.nlm.nih.gov/pubmed/10453328
Alpha-ketoglutarate (AKG), an endogenous intermediary metabolite in the Krebs cycle, is a molecule involved in multiple metabolic and cellular pathways. As an intermediate of the tricarboxylic acid cycle, AKG is essential for the oxidation of fatty acids, amino acids, and glucose. Extracellular AKG is a significant source of energy for cells of the gastrointestinal tract. As a precursor for the synthesis of glutamate and glutamine in multiple tissues (including liver, skeletal muscle, heart, brain, and white adipose tissue), AKG bridges carbohydrate and nitrogen metabolism for both conservation of amino acids and ammonia detoxification. Additionally, emerging evidence shows that AKG is a regulator of gene expression and cell signaling pathways (including the mammalian target of rapamycin and AMPactivated protein kinase). Thus, AKG is an attractive dietary supplement in animal and human nutrition to improve cellular energy status, immunity, and health.AKG can decrease protein catabolism and increase protein synthesis to enhance bone tissue formation in the skeletal muscles and can be used in clinical applications. In addition to these health benefits, a recent study has shown that AKG can extend the lifespan of adult Caenorhabditis elegans by inhibiting ATP synthase and TOR. Orally, AKG is used for kidney disease, gastrointestinal disorders, bacterial overgrowth, intestinal toxemia, liver dysfunction, and chronic candidiasis. It is also used for improving peak athletic performance, improving amino acid metabolism in hemodialysis patients, and cataracts.
Intravenously, AKG is used for preventing ischemic injury during heart surgery, improving renal blood flow after heart surgery, and preventing muscle protein depletion after surgery or trauma.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2062350 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24828042 |
|||
Target ID: hydrogen peroxide Sources: https://www.ncbi.nlm.nih.gov/pubmed/21281600 |
|||
Target ID: CHEMBL2816 |
|||
Target ID: P00367 Gene ID: 2746.0 Gene Symbol: GLUD1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/27326424 |
|||
Target ID: WP408 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27326424 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10601539 http://www.webmd.com/vitamins-supplements/ingredientmono-642-ornithine%20ketoglutarate.aspx?activeingredientid=642&activeingredientname=ornithine%20ketoglutarate https://www.ncbi.nlm.nih.gov/pubmed/15465801 http://www.gjav.eu/ornithine-alpha-ketoglutarate/ https://www.ncbi.nlm.nih.gov/pubmed/10453328 |
Primary | ORNITHINE ALPHA-KETOGLUTARATE Approved UseOrnithine alpha-ketoglutarate (OKG) administration improves nutritional status in chronically malnourished (e.g., elderly) and acutely malnourished patients (especially burn and trauma patients). |
||
| Primary | ALPHA-KETOGLUTARATE Approved UseOrally, alpha-ketoglutarate is used for kidney disease, gastrointestinal disorders, bacterial overgrowth, intestinal toxemia, liver dysfunction, and chronic candidiasis. It is also used for improving peak athletic performance, improving amino acid metabolism in hemodialysis patients, and cataracts.
Intravenously, alpha-ketoglutarate is used for preventing ischemic injury during heart surgery, improving renal blood flow after heart surgery, and preventing muscle protein depletion after surgery or trauma. |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
39 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21787714/ |
11.7 mg single, respiratory dose: 11.7 mg route of administration: Respiratory experiment type: SINGLE co-administered: |
OXOGLURIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
376 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21787714/ |
11.7 mg single, respiratory dose: 11.7 mg route of administration: Respiratory experiment type: SINGLE co-administered: |
OXOGLURIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21787714/ |
11.7 mg single, respiratory dose: 11.7 mg route of administration: Respiratory experiment type: SINGLE co-administered: |
OXOGLURIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
100% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24770989/ |
OXOGLURIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
20 g single, oral Highest studied dose |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
Other AEs: Nausea, Tachycardia... |
30000 mg/h single, intravenous Highest studied dose Dose: 30000 mg/h Route: intravenous Route: single Dose: 30000 mg/h Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Nausea | 20 g single, oral Highest studied dose |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
|
| Tachycardia | grade 1 | 20 g single, oral Highest studied dose |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Alpha-Ketoglutarate as a Molecule with Pleiotropic Activity: Well-Known and Novel Possibilities of Therapeutic Use. | 2017-02 |
|
| The biological role of a-ketoglutaric acid in physiological processes and its therapeutic potential. | 2016-07-15 |
|
| The Physiological Basis and Nutritional Function of Alpha-ketoglutarate. | 2015 |
|
| The metabolite α-ketoglutarate extends lifespan by inhibiting ATP synthase and TOR. | 2014-06-19 |
|
| Artefacts in cell culture: α-Ketoglutarate can scavenge hydrogen peroxide generated by ascorbate and epigallocatechin gallate in cell culture media. | 2011-03-04 |
|
| The absorption, tissue distribution and excretion of enteraly administered alpha-ketoglutarate in rats. | 2008-04 |
|
| In vitro and in vivo evaluation of various carbonyl compounds against cyanide toxicity with particular reference to alpha-ketoglutaric acid. | 2008 |
|
| Ornithine alpha-ketoglutarate as a potent precursor of arginine and nitric oxide: a new job for an old friend. | 2004-10 |
|
| Effect of alpha-ketoglutarate and oxaloacetate on brain mitochondrial DNA damage and seizures induced by kainic acid in mice. | 2003-07-20 |
|
| Nutritional and clinical efficacy of ornithine alpha-ketoglutarate in severe burn patients. | 1999-10 |
|
| The use of alpha-ketoglutarate salts in clinical nutrition and metabolic care. | 1999-01 |
|
| [A controlled trial of ornithine alpha-ketoglutarate in neuro-traumatology]. | 1986-10 |
|
| Effect of ornithine alpha ketoglutarate (OAKG) on the response of brain metabolism to hypoxia in the dog. | 1978-05-01 |
|
| [1 (+) ornithine alpha ketoglutarate in hepatic encephalopathy]. | 1970-06-20 |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.klaire.com/prod/proddetail.asp?id=V135-06
1 capsule daily
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18161514
It was investigated the efficacy of several carbonyl compounds and their metabolites or nutrients with alpha-ketoglutaric acid (A-KG), citric acid, succinic acid, maleic acid, malic acid, fumaric and oxaloacetic acid, glucose, sucrose, fructose, mannitol, sorbitol, dihydroxyacetone, and glyoxal (5 or 10 mM; -10 min) against toxicity of potassium cyanide (KCN; 10 mM) in rat thymocytes in vitro. Six hours after KCN, cell viability measured by MTT assay and crystal violet dye exclusion revealed maximum cytoprotection by A-KG, followed by oxaloacetic acid. A-KG also resolved the leakage of intracellular lactate dehydrogenase, loss in nuclear integrity (propidium iodide staining), and altered mitochondrial membrane potential (rhodamine 123 assay) as a result of cyanide toxicity. Protection Index (ratio of LD(50) of KCN in protected and unprotected animals; PI) of all the compounds (oral; 1.0 g/kg; -10 min) determined in male mice, revealed that maximum protection was afforded by A-KG (7.6 PI), followed by oxaloacetic acid (6.4 PI). Comparative evaluation of various salts of A-KG alone or with STS (intraperitoneal; 1.0 g/kg; -15 min) showed that maximum protection was conferred by disodium anhydrous salt of A-KG, which also significantly prevented the inhibition of brain cytochrome oxidase caused by 0.75 LD(50) KCN.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:49:07 GMT 2025
by
admin
on
Mon Mar 31 17:49:07 GMT 2025
|
| Record UNII |
8ID597Z82X
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
JECFA EVALUATION |
2-OXOPENTANEDIOIC ACID
Created by
admin on Mon Mar 31 17:49:07 GMT 2025 , Edited by admin on Mon Mar 31 17:49:07 GMT 2025
|
||
|
LOINC |
27271-6
Created by
admin on Mon Mar 31 17:49:07 GMT 2025 , Edited by admin on Mon Mar 31 17:49:07 GMT 2025
|
||
|
LOINC |
29507-1
Created by
admin on Mon Mar 31 17:49:07 GMT 2025 , Edited by admin on Mon Mar 31 17:49:07 GMT 2025
|
||
|
LOINC |
13678-8
Created by
admin on Mon Mar 31 17:49:07 GMT 2025 , Edited by admin on Mon Mar 31 17:49:07 GMT 2025
|
||
|
LOINC |
21040-1
Created by
admin on Mon Mar 31 17:49:07 GMT 2025 , Edited by admin on Mon Mar 31 17:49:07 GMT 2025
|
||
|
DSLD |
1052 (Number of products:129)
Created by
admin on Mon Mar 31 17:49:07 GMT 2025 , Edited by admin on Mon Mar 31 17:49:07 GMT 2025
|
||
|
LOINC |
69802-7
Created by
admin on Mon Mar 31 17:49:07 GMT 2025 , Edited by admin on Mon Mar 31 17:49:07 GMT 2025
|
||
|
LOINC |
69803-5
Created by
admin on Mon Mar 31 17:49:07 GMT 2025 , Edited by admin on Mon Mar 31 17:49:07 GMT 2025
|
||
|
LOINC |
1817-6
Created by
admin on Mon Mar 31 17:49:07 GMT 2025 , Edited by admin on Mon Mar 31 17:49:07 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000128818
Created by
admin on Mon Mar 31 17:49:07 GMT 2025 , Edited by admin on Mon Mar 31 17:49:07 GMT 2025
|
PRIMARY | |||
|
17391
Created by
admin on Mon Mar 31 17:49:07 GMT 2025 , Edited by admin on Mon Mar 31 17:49:07 GMT 2025
|
PRIMARY | |||
|
455
Created by
admin on Mon Mar 31 17:49:07 GMT 2025 , Edited by admin on Mon Mar 31 17:49:07 GMT 2025
|
PRIMARY | |||
|
4207
Created by
admin on Mon Mar 31 17:49:07 GMT 2025 , Edited by admin on Mon Mar 31 17:49:07 GMT 2025
|
PRIMARY | |||
|
DTXSID5033179
Created by
admin on Mon Mar 31 17:49:07 GMT 2025 , Edited by admin on Mon Mar 31 17:49:07 GMT 2025
|
PRIMARY | |||
|
8ID597Z82X
Created by
admin on Mon Mar 31 17:49:07 GMT 2025 , Edited by admin on Mon Mar 31 17:49:07 GMT 2025
|
PRIMARY | |||
|
C1505
Created by
admin on Mon Mar 31 17:49:07 GMT 2025 , Edited by admin on Mon Mar 31 17:49:07 GMT 2025
|
CONCEPT | Dietary Supplement | ||
|
30915
Created by
admin on Mon Mar 31 17:49:07 GMT 2025 , Edited by admin on Mon Mar 31 17:49:07 GMT 2025
|
PRIMARY | |||
|
DB08845
Created by
admin on Mon Mar 31 17:49:07 GMT 2025 , Edited by admin on Mon Mar 31 17:49:07 GMT 2025
|
PRIMARY | |||
|
51
Created by
admin on Mon Mar 31 17:49:07 GMT 2025 , Edited by admin on Mon Mar 31 17:49:07 GMT 2025
|
PRIMARY | |||
|
206-330-3
Created by
admin on Mon Mar 31 17:49:07 GMT 2025 , Edited by admin on Mon Mar 31 17:49:07 GMT 2025
|
PRIMARY | |||
|
328-50-7
Created by
admin on Mon Mar 31 17:49:07 GMT 2025 , Edited by admin on Mon Mar 31 17:49:07 GMT 2025
|
PRIMARY | |||
|
ALPHA-KETOGLUTARIC ACID
Created by
admin on Mon Mar 31 17:49:07 GMT 2025 , Edited by admin on Mon Mar 31 17:49:07 GMT 2025
|
PRIMARY | |||
|
m6620
Created by
admin on Mon Mar 31 17:49:07 GMT 2025 , Edited by admin on Mon Mar 31 17:49:07 GMT 2025
|
PRIMARY | Merck Index | ||
|
17511
Created by
admin on Mon Mar 31 17:49:07 GMT 2025 , Edited by admin on Mon Mar 31 17:49:07 GMT 2025
|
PRIMARY | RxNorm | ||
|
C83527
Created by
admin on Mon Mar 31 17:49:07 GMT 2025 , Edited by admin on Mon Mar 31 17:49:07 GMT 2025
|
PRIMARY | |||
|
8ID597Z82X
Created by
admin on Mon Mar 31 17:49:07 GMT 2025 , Edited by admin on Mon Mar 31 17:49:07 GMT 2025
|
PRIMARY | |||
|
SUB36364
Created by
admin on Mon Mar 31 17:49:07 GMT 2025 , Edited by admin on Mon Mar 31 17:49:07 GMT 2025
|
PRIMARY | |||
|
16810
Created by
admin on Mon Mar 31 17:49:07 GMT 2025 , Edited by admin on Mon Mar 31 17:49:07 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |